# A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

> **NCT04255862** · PHASE1 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 71 (actual)

## Conditions studied

- Healthy Study Participants

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT04255862
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-12
- **Primary completion:** 2021-04-26
- **Final completion:** 2021-04-26
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Study recruitment temporarily halted due to difficulties executing the study under the COVID-19 pandemic
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04255862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04255862, "A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04255862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*